Reminder for ADMA Biologics Investors on Class Action Lawsuit
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that August 10, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026.
- Allegations: A report by Culper Research alleges that ADMA engaged in 'channel stuffing' and undisclosed related party transactions, resulting in a real growth rate of -3% in 2025 compared to the reported 20%, which has led to significant investor losses.
- Stock Price Impact: Following this news, ADMA's stock price fell by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, which severely harmed investor interests.
- Legal Claims: The lawsuit alleges that ADMA made materially false and misleading statements throughout the class period, failing to disclose adverse facts about its business, operations, and prospects, which has significantly undermined investor confidence in the company.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Reminder for ADMA Biologics Investors on Class Action Lawsuit
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that August 10, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026.
- Allegations: A report by Culper Research alleges that ADMA engaged in 'channel stuffing' and undisclosed related party transactions, resulting in a real growth rate of -3% in 2025 compared to the reported 20%, which has led to significant investor losses.
- Stock Price Impact: Following this news, ADMA's stock price fell by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, which severely harmed investor interests.
- Legal Claims: The lawsuit alleges that ADMA made materially false and misleading statements throughout the class period, failing to disclose adverse facts about its business, operations, and prospects, which has significantly undermined investor confidence in the company.
See More
Investor Alert: Class Action Lawsuit Notices
- Lawsuit Timeline: The class action lawsuit for Via Transportation, Inc. covers the period from September 9, 2025, to June 9, 2026, with a lead plaintiff deadline of August 10, 2026, meaning investors must act promptly to avoid losing their rights to claim.
- False Statements Allegations: The lawsuit alleges that Via Transportation's management made materially false and misleading statements during this period, failing to disclose a decline in annual recurring revenue per customer and regulatory issues that could hinder its expansion strategy in Germany, negatively impacting the company's future business outlook.
- Zillow Class Action: Zillow Group, Inc. has a class action lawsuit covering the period from February 11, 2025, to May 7, 2026, with a similar lead plaintiff deadline of August 10, 2026, emphasizing the need for investors to act quickly to preserve their rights.
- Antitrust Risks: The lawsuit claims that Zillow failed to disclose that its agreement with Redfin was an acquisition rather than a partnership, and downplayed legal exposure amid an antitrust lawsuit, which could severely impact its stock price and market confidence.
See More
Notice to ADMA Biologics Shareholders Regarding Class Action Lawsuit
- Lawsuit Background: The Gross Law Firm has issued a notice encouraging shareholders who purchased ADMA Biologics shares between August 9, 2024, and March 25, 2026, to contact them for potential lead plaintiff appointment, indicating significant legal risks for the company.
- Allegations Details: The lawsuit alleges that ADMA Biologics made materially false and misleading statements during this period, including undisclosed related party transactions and channel stuffing to create a false appearance of revenue, highlighting inadequate internal controls that may have led to shareholder losses.
- Participation Requirements: Shareholders must register by August 10, 2026, to participate in the class action, and upon registration, they will receive updates through portfolio monitoring software, ensuring they stay informed about the case's progress.
- Law Firm's Expertise: The Gross Law Firm is committed to protecting investors' rights, focusing on those who have suffered losses due to fraud and illegal business practices, emphasizing its expertise and successful track record in class action lawsuits.
See More
ADMA Biologics Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against ADMA Biologics for violations of §§10(b) and 20(a) of the Securities Exchange Act, affecting securities purchased between August 9, 2024, and March 25, 2026, potentially impacting numerous investors' rights.
- False Statement Allegations: The complaint alleges that ADMA made false and misleading statements during this period, involving undisclosed related party transactions and channel stuffing practices, leading to market misconceptions about its financial health, thus affecting investor decisions.
- Lack of Internal Controls: ADMA failed to maintain adequate internal controls, resulting in its public statements being false and materially misleading throughout the class period, causing investors to suffer losses upon learning the truth, which could have severe financial implications.
- Investor Rights Protection: The Schall Law Firm encourages affected investors to contact them before August 10, 2026, to participate in the lawsuit and seek compensation for their losses, highlighting the importance of protecting investor rights and the necessity of legal support.
See More
Notice of Class Action Lawsuit Against ADMA Biologics
- Class Action Timeline: Purchasers of ADMA Biologics securities between August 9, 2024, and March 25, 2026, should note that the deadline to apply as lead plaintiff is August 10, 2026, and failure to act may result in loss of compensation rights.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false statements during the class period, including undisclosed related party transactions and channel stuffing, which led to investor losses when the truth emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to ensure effective representation in the lawsuit and avoid inexperienced intermediaries.
See More
Class Action Lawsuit Filed Against ADMA Biologics
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against ADMA Biologics in the U.S. District Court for New Jersey on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that ADMA failed to disclose related party transactions, engaged in channel stuffing to inflate revenue, and lacked adequate internal controls, potentially misleading investors about the company's financial health and impacting their investment decisions.
- Stock Price Decline Impact: Following the March 24, 2026, short report by Culper Research, which accused ADMA of reporting fictitious growth, the stock price fell by $2.26, or 16.63%, closing at $11.33, reflecting market concerns over the company's financial transparency.
- Investor Action Call: The law firm encourages investors who suffered losses during the class period to contact them to understand their legal rights and potential remedies, indicating that the ongoing legal challenges may affect the company's future market performance.
See More
Reminder for ADMA Biologics Investors on Class Action Lawsuit
- Lawsuit Background: Glancy Prongay Wolke & Rotter LLP reminds investors that August 10, 2026, is the deadline to file a lead plaintiff motion in the class action for those who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026.
- Allegations: A report by Culper Research alleges that ADMA engaged in 'channel stuffing' and undisclosed related party transactions, resulting in a real growth rate of -3% in 2025 compared to the reported 20%, which has led to significant investor losses.
- Stock Price Impact: Following this news, ADMA's stock price fell by $3.96, or 29.1%, over two trading days, closing at $9.63 per share, which severely harmed investor interests.
- Legal Claims: The lawsuit alleges that ADMA made materially false and misleading statements throughout the class period, failing to disclose adverse facts about its business, operations, and prospects, which has significantly undermined investor confidence in the company.
See More
Investor Alert: Class Action Lawsuit Notices
- Lawsuit Timeline: The class action lawsuit for Via Transportation, Inc. covers the period from September 9, 2025, to June 9, 2026, with a lead plaintiff deadline of August 10, 2026, meaning investors must act promptly to avoid losing their rights to claim.
- False Statements Allegations: The lawsuit alleges that Via Transportation's management made materially false and misleading statements during this period, failing to disclose a decline in annual recurring revenue per customer and regulatory issues that could hinder its expansion strategy in Germany, negatively impacting the company's future business outlook.
- Zillow Class Action: Zillow Group, Inc. has a class action lawsuit covering the period from February 11, 2025, to May 7, 2026, with a similar lead plaintiff deadline of August 10, 2026, emphasizing the need for investors to act quickly to preserve their rights.
- Antitrust Risks: The lawsuit claims that Zillow failed to disclose that its agreement with Redfin was an acquisition rather than a partnership, and downplayed legal exposure amid an antitrust lawsuit, which could severely impact its stock price and market confidence.
See More
Notice to ADMA Biologics Shareholders Regarding Class Action Lawsuit
- Lawsuit Background: The Gross Law Firm has issued a notice encouraging shareholders who purchased ADMA Biologics shares between August 9, 2024, and March 25, 2026, to contact them for potential lead plaintiff appointment, indicating significant legal risks for the company.
- Allegations Details: The lawsuit alleges that ADMA Biologics made materially false and misleading statements during this period, including undisclosed related party transactions and channel stuffing to create a false appearance of revenue, highlighting inadequate internal controls that may have led to shareholder losses.
- Participation Requirements: Shareholders must register by August 10, 2026, to participate in the class action, and upon registration, they will receive updates through portfolio monitoring software, ensuring they stay informed about the case's progress.
- Law Firm's Expertise: The Gross Law Firm is committed to protecting investors' rights, focusing on those who have suffered losses due to fraud and illegal business practices, emphasizing its expertise and successful track record in class action lawsuits.
See More
ADMA Biologics Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm alerts investors of a class action lawsuit against ADMA Biologics for violations of §§10(b) and 20(a) of the Securities Exchange Act, affecting securities purchased between August 9, 2024, and March 25, 2026, potentially impacting numerous investors' rights.
- False Statement Allegations: The complaint alleges that ADMA made false and misleading statements during this period, involving undisclosed related party transactions and channel stuffing practices, leading to market misconceptions about its financial health, thus affecting investor decisions.
- Lack of Internal Controls: ADMA failed to maintain adequate internal controls, resulting in its public statements being false and materially misleading throughout the class period, causing investors to suffer losses upon learning the truth, which could have severe financial implications.
- Investor Rights Protection: The Schall Law Firm encourages affected investors to contact them before August 10, 2026, to participate in the lawsuit and seek compensation for their losses, highlighting the importance of protecting investor rights and the necessity of legal support.
See More
Notice of Class Action Lawsuit Against ADMA Biologics
- Class Action Timeline: Purchasers of ADMA Biologics securities between August 9, 2024, and March 25, 2026, should note that the deadline to apply as lead plaintiff is August 10, 2026, and failure to act may result in loss of compensation rights.
- Lawsuit Background: The lawsuit alleges that ADMA Biologics made materially false statements during the class period, including undisclosed related party transactions and channel stuffing, which led to investor losses when the truth emerged, negatively impacting the company's reputation and stock price.
- Law Firm Credentials: The Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, being ranked No. 1 by ISS Securities Class Action Services in 2017, demonstrating its expertise and success in this field.
- Investor Action Recommendations: Investors can visit the Rosen Law Firm's website or call the toll-free number for more information, emphasizing the importance of selecting qualified legal counsel to ensure effective representation in the lawsuit and avoid inexperienced intermediaries.
See More
Class Action Lawsuit Filed Against ADMA Biologics
- Class Action Initiation: Bragar Eagel & Squire has filed a class action lawsuit against ADMA Biologics in the U.S. District Court for New Jersey on behalf of investors who purchased securities between August 9, 2024, and March 25, 2026, indicating significant legal risks for the company.
- Allegation Details: The lawsuit alleges that ADMA failed to disclose related party transactions, engaged in channel stuffing to inflate revenue, and lacked adequate internal controls, potentially misleading investors about the company's financial health and impacting their investment decisions.
- Stock Price Decline Impact: Following the March 24, 2026, short report by Culper Research, which accused ADMA of reporting fictitious growth, the stock price fell by $2.26, or 16.63%, closing at $11.33, reflecting market concerns over the company's financial transparency.
- Investor Action Call: The law firm encourages investors who suffered losses during the class period to contact them to understand their legal rights and potential remedies, indicating that the ongoing legal challenges may affect the company's future market performance.
See More
